{"entity":{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","aka":[],"tldr":"Iovance Biotherapeutics, of San Carlos, California, makes Amtagvi (lifileucel), the first approved tumour-infiltrating lymphocyte therapy, a treatment grown from a patient's own tumour-resident immune cells and approved in melanoma. Making it fast and cheap enough to reach most eligible patients is its open question.","summary":"Iovance Biotherapeutics, based in San Carlos, California, and listed as IOVA, makes Amtagvi, or lifileucel, the first approved tumour-infiltrating lymphocyte therapy. Lifileucel was approved in melanoma on the C-144-01 trial and in the European Union in 2025, TILVANCE-301 tests it in the first line, trials are running in lung and cervical cancer, and IOV-4001 is a next-generation PD-1-inactivated TIL product. OnCo links it to melanoma, to the TIL therapy technology, to the bottleneck of manufacturing cost and time for living medicines, and to ideas on selecting patients by whether their tumour holds reactive T cells. Whether TIL therapy can be made fast and cheap enough to reach most eligible patients is the open question. Lifileucel has its own page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Iovance_Biotherapeutics","links":[{"label":"Official website","url":"https://www.iovance.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":["lifileucel","aldesleukin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05727904","nct07288203","nct06481592","nct06940739","nct04614103","nct05361174"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Carlos, CA","country":"US","companyType":"cell-therapy","website":"https://www.iovance.com","ticker":"IOVA","investors":[],"funding":[]},"route":"/companies/iovance/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"trial":[{"id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","route":"/trials/nct07743723/"},{"id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","route":"/trials/nct06481592/"},{"id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","route":"/trials/nct07288203/"},{"id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","route":"/trials/nct05361174/"},{"id":"nct06940739","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","route":"/trials/nct06940739/"},{"id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct04614103/"},{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/"},{"id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","route":"/trials/nct05727904/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"idea":[{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/"},{"id":"idea-bio1-organoid-cell-therapy-potency","kind":"idea","name":"Use patient organoids to check a cell therapy will work before infusing it","route":"/ideas/idea-bio1-organoid-cell-therapy-potency/"}],"paper":[{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/"}]}}